My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Natera, Inc. - Common Stock (NQ:NTRA)

229.12 -2.18 (-0.94%)

Streaming Delayed Price Updated: 12:43 PM EST, Dec 30, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Natera, Inc. - Common Stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

18 19 Next >

A Glimpse Into The Expert Outlook On Natera Through 9 Analysts ↗

February 20, 2024

Via Benzinga

Natera Announces Fourth Quarter and Fiscal 2023 Earnings Conference Call

February 20, 2024

From Natera, Inc.

Via Business Wire

There are signs that NASDAQ:NTRA may be ready to breakout. ↗

February 16, 2024

NATERA INC (NASDAQ:NTRA) has a good technical rating of 10 out of 10 and could possibly break out.

Via Chartmill

3 Strong Buy Biotech Stocks to Add to Your February Must-Watch List ↗

February 06, 2024

These biotech stocks offer investors huge potential in the future. Investors may want to consider these equities to enter the industry.

Via InvestorPlace

NVTA Stock: Invitae Plunges 78% on the Brink of Bankruptcy ↗

February 06, 2024

NVTA stock tumbled yesterday amid a report that the firm could declare bankruptcy soon. The shares were halted for news pending.

Via InvestorPlace

Topics Bankruptcy

Expert Ratings For Natera ↗

January 17, 2024

Via Benzinga

Natera Inc. (NASDAQ: NTRA) Records 52-Week High Tuesday Morning

January 09, 2024

Via Investor Brand Network

The Analyst Landscape: 8 Takes On Natera ↗

December 29, 2023

Via Benzinga

SoftBank-Backed Genetic Testing Invitae's Descent from $7B Valuation to Near-Bankruptcy ↗

February 05, 2024

Invitae's financial challenges as it grapples with a $1.5 billion debt burden. Explore the company's strategic options amidst potential bankruptcy, asset shedding, and cost-cutting measures.

Via Benzinga

Topics Bankruptcy

Pinterest, Checkpoint Therapeutics And 2 Other Stocks Insiders Are Selling ↗

February 05, 2024

The Nasdaq 100 closed higher by around 300 points on Friday. Investors, meanwhile, focused on some notable insider trades.

Via Benzinga

New Study Validates Signatera™ in Endometrial Cancer

February 05, 2024

From Natera, Inc.

Via Business Wire

New Publication Demonstrates Signatera’s Ability to Risk Stratify and Detect Recurrence Early in Resected Stage I-II Lung Cancer

January 30, 2024

From Natera, Inc.

Via Business Wire

Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030

January 30, 2024

EQNX::TICKER_START (OTCQB:TDSGF),(TSXV:TELO),(NYSE:BMY),(NYSE:TMO),(NASDAQ:NTRA),(NASDAQ:NEO) EQNX::TICKER_END

Via FinancialNewsMedia

Jury Rules in Favor of Natera in Patent Infringement Lawsuit Against CareDx; Awards $96.3 Million in Damages to Natera in Lost Profits and Past Royalties

January 29, 2024

From Natera, Inc.

Via Business Wire

Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030

January 30, 2024

From FN Media Group LLC

Via GlobeNewswire

Nature Medicine Publishes Two Studies Highlighting Signatera’s Clinical Utility in Patients with Gastrointestinal Malignancies

January 25, 2024

From Natera, Inc.

Via Business Wire

Natera Acquires Reproductive Health Assets from Invitae

January 22, 2024

From Natera, Inc.

Via Business Wire

Natera to Present New Data from the CIRCULATE-Japan and BESPOKE CRC Studies at ASCO GI 2024 Supporting Signatera’s Clinical Utility in CRC

January 18, 2024

From Natera, Inc.

Via Business Wire

Natera Hits A Nearly Two-Year High After Notching A Win In A Patent Battle ↗

January 17, 2024

The company must pay $57 million in damages, but that's far less than expected.

Via Investor's Business Daily

Topics Intellectual Property

Why DatChat Shares Are Trading Lower By Around 33%; Here Are 20 Stocks Moving Premarket ↗

January 17, 2024

Shares of DatChat, Inc. (NASDAQ: DATS) fell sharply in pre-market trading after announcing a proposed underwritten public offering of common stock. DatChat shares dipped 33.1% to $2.13 in pre-market...

Via Benzinga

Progress Software Posts Strong Q4 Results, Joins Impinj, REGENXBIO And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session ↗

January 17, 2024

U.S. stock futures were lower this morning, with the Dow Jones futures falling more than 100 points on Wednesday. Shares of Progress Software Corporation (NASDAQ: PRGS) rose in pre-market trading as...

Via Benzinga

Topics Stocks

Natera Provides Update on Ravgen Trial

January 16, 2024

From Natera, Inc.

Via Business Wire

Bull of the Day - NeoGenomics ↗

January 12, 2024

But in late December, shares took a big hit on patent litigation with competitor Natera. Let's review the primary commercial business of NEO and then that will help put the legal news into context.

Via Talk Markets

Topics Intellectual Property

Natera Announces Preliminary Fourth Quarter and Full Year 2023 Revenues

January 09, 2024

From Natera, Inc.

Via Business Wire

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet ↗

December 29, 2023

Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and warrant attention.

Via Benzinga

Expedia To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Friday ↗

December 29, 2023

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

Natera to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

December 29, 2023

From Natera, Inc.

Via Business Wire

US Court Prohibits NeoGenomics To Sell Type Of Diagnostic Kits To Detect Smaller Number Of Cancer Cells, Favoring Natera In Lawsuit ↗

December 28, 2023

Shares of NeoGenomics Inc (NASDAQ: NEO) fell Thursday after the company received a preliminary injunction from a North Carolina district court, which prohibits the company from

Via Benzinga

Natera Wins Preliminary Injunction in Patent Infringement Lawsuit Against NeoGenomics’ RaDaR Test

December 27, 2023

From Natera, Inc.

Via Business Wire

NATERA ALERT: Bragar Eagel & Squire, P.C. is Investigating Natera, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

December 26, 2023

From Bragar Eagel & Squire, P.C.

Via Business Wire

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

18 19 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.